Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
1.942 EUR | -1.92% | -3.62% | -45.37% |
Apr. 04 | AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada | MT |
Apr. 03 | AB Science: reconsideration possible for masitinib in ALS | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-45.37% | 108M | |
+11.94% | 9.18B | |
-16.33% | 4.79B | |
+6.40% | 3.97B | |
+26.98% | 3.98B | |
+27.59% | 2.56B | |
-26.55% | 2.29B | |
-25.02% | 2.23B | |
+5.82% | 1.92B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- AB Stock
- News AB Science
- AB Science : French Agency Approves AB Science's Measures To Ensure Safety In Ongoing Studies